return equiti ttm
post-cal model adjust solid book wait organ top-
updat model iqvia follow earn releas wednesday
februari quarter result slightli expect better-than-
expect ebit margin contribut out-performance compar target
book backlog also expect revenu commerci
solut apples-to-appl basi guidanc consist model
decreas ep estim lower reflect
time impact new account standard maintain outperform rate
iqvia premis good book declin integr nois allow
organ revenu growth acceler time
iqvia finish wednesday approxim suspect investor concern
somewhat abat better-than-expect solut top-lin commentari
come year manag previous suggest novemb analyst day
consolid top-lin growth averag midsingl digit next three
year prompt fear solut outlook would wors
guidanc segment old account methodolog call report
revenu growth midpointnic ahead report growth
anoth book-to-bil ratio drove backlog growth also bolster
abil solut eventu outpac cro market believ
backlog growth correl organ revenu growth time
durat convers rate stabl
view key question remain true level organ growth
expect solut segment consolid busi
manag give explicit organ revenu guidanc transpar
around acquisit contribut given period lack detail exhibit
estim guidanc impli approxim foreign exchang benefit
current rate benefit acquisit impli underli
organ growth adjust new account rule aggreg
steadi estim exhibit
iqvia integr inform technology-en healthcar servic provid annual revenu
base approach billion form merger quintil im health compani employ
roughli employe oper countri compani world lead provid
pharmaceut sale prescript data leader outsourc drug develop commerci
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
fourth quarter full year observ
compani book-to-bil around quarter estim ratio backlog
growth give us addit comfort better top-lin growth year possibl estim
translat organ revenu growth approxim overal significantli affect declin
 solut segmentup solut full year
commerci solut increas constant-curr basi quarter full year
adjust million defer revenu adjust year ago perform segment million
targetdriven believ on-going technolog acquisit balanc commerci segment
continu steadi perform organ growth around
 increas constant-curr basi quarter full year solid
net new busi driven higher level rfp strong client uptak next-gen cro offer
believ organ growth segment period still market believ
acceler busi come one two year critic drive out-performance stock
level
integr decreas constant-curr basi quarter declin
full year commentari busi still quit cautiou double-digit declin expect
come year appear compani refocu attempt improv perform oppos
sell busi
make adjust first quarter estim reflect manag initi guidanc
increas revenu target million billion quarter given new account standard
increas ebitda target million adjust below-the-lin item come ep estim
increas revenu target full year billion billion decreas ep
estim full year essenti reduct driven new account
increas revenu estim billion billion decreas ebitda
million billion also decreas ep estim
valuat stock thought
follow wednesday increas iqvia trade time revis estim valuat
slight premium cro group time slightli stock five-year averag time
maintain outperform rate iqvia time given continu solid book trend expect
translat better top-lin growth beyond updat model iqvia follow
organ growthacquisitionsfx benefitasc report growth unadjust revenuesa report growth adjust revenuescommerci engag compani report william blair estim william blair
exhibit updat iqvia hold incom statement summari
profit gener administr expens assum synergi includ estim amort incom includ option beg incom expens tax investe non-controlling interests/minor hedg incom tax non control item net incom excl non-recurring item incl option beg averag share outstand averag share outstand analysi gross excl foreign exchang effect pro forma beg organ pro forma beg incom excl non-recur excl non-recur item incl blair compani estimatesourc compani report william blair compani llc estim import disclosur
